Ubs Group Ag Lyra Therapeutics, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LYRA
# of Institutions
61Shares Held
32.2MCall Options Held
21.1KPut Options Held
400-
Perceptive Advisors LLC New York, NY12.8MShares$2.3 Million0.09% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.77MShares$859,1060.0% of portfolio
-
Black Rock Inc. New York, NY2.83MShares$509,3960.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.78MShares$500,4460.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.78MShares$320,2670.0% of portfolio
About Lyra Therapeutics, Inc.
- Ticker LYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,826,400
- Market Cap $5.73M
- Description
- Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...